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==========

We explored the feasibility of assessing real-world patient experiences regarding their overall treatment experience for ankylosing spondylitis (AS) using simple questions in plain language to assess their treatment experience and satisfaction; in this study, their experience with secukinumab was evaluated.The majority of respondents reported AS symptom improvement, which was achieved within 6 months, and satisfaction with secukinumab.Our data indicate that assessing patient-reported perspectives of patients with AS using a web-based survey may be a practical means to provide insights into treatment experience and satisfaction.

Introduction {#Sec1}
============

Ankylosing spondylitis (AS) is a chronic, inflammatory rheumatic disease that predominantly affects the axial skeleton, resulting in bony ankylosis and often leading to impairment or loss of physical function \[[@CR1]--[@CR3]\]. Patients with AS are known to have a higher risk for many co-morbid conditions, including cardiovascular disease and osteoporosis \[[@CR4]--[@CR9]\]. AS is associated with decreased quality of life (QOL), increased mortality, and substantial healthcare-related costs, therefore imposing a high burden on patients, their caregivers, and society \[[@CR10]\].

Based on recommendations from the Assessment of SpondyloArthritis international Society/European League Against Rheumatism \[[@CR11]\], American College of Rheumatology, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network \[[@CR12]\], the first-line treatment for AS should include nonsteroidal anti-inflammatory drugs (NSAIDs) for the management of pain and stiffness. For patients with an inadequate response to NSAIDs, or who experience adverse effects, biologics have emerged as a novel anti-inflammatory therapy \[[@CR13]\]. Current practice suggests tumor necrosis factor inhibitors as first-line biologic therapy for patients with persistent disease activity despite NSAID treatment \[[@CR14]\].

Significant progress has been made in our understanding of AS in the last decade, and interleukin (IL)-17 has been identified as a key cytokine driving inflammation in AS \[[@CR15]--[@CR17]\]. Several studies suggest that the IL-17 pathway is a promising target in the treatment of AS \[[@CR18]--[@CR20]\]. Additionally, patients with AS have elevated numbers of IL-17-producing cells \[[@CR21]--[@CR23]\]. Secukinumab, a fully human monoclonal antibody targeting IL-17A, is the first and only approved non-TNFi biologic approved in the USA for the treatment of AS; it is also indicated for the treatment of psoriasis and psoriatic arthritis (PsA) \[[@CR24]\].

In two phase III placebo-controlled trials (MEASURE 1 and MEASURE 2), secukinumab showed efficacy in reducing the signs and symptoms of AS at week 16 following treatment initiation; benefits were sustained through week 52 \[[@CR25], [@CR26]\]. Based on MEASURE 1 and MEASURE 2, secukinumab was approved in the USA for the treatment of active AS \[[@CR27]\]. Even though secukinumab has demonstrated efficacy in randomized clinical trials, little is known about patient experience with secukinumab for the treatment of AS in real-world settings. Disease activity measures, such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Assessment of SpondyloArthritis international Society criteria, are routinely used to measure treatment efficacy in clinical trials and are recommended for disease assessment in clinical practice \[[@CR28]\]. However, these composite disease activity measures do not fully capture patient perspectives on treatment effectiveness. Additionally, randomized clinical trials often do not account for patient experience and satisfaction with treatment.

In this exploratory study, we sought to determine the feasibility of garnering and understanding real-world patient narratives with regard to their treatment experience and satisfaction. We surveyed patients with active AS who were receiving treatment with secukinumab and collected their accounts of AS symptom improvement and treatment satisfaction in a real-world setting in the USA. Our overarching goal is to develop a practical means of capturing treatment-related experiences from the patient perspective.

Methods {#Sec2}
=======

Study Design and Patient Population {#Sec3}
-----------------------------------

Data were collected from a cross-sectional, web-based survey in the USA. A random sample of patients with AS or PsA were invited by email to participate in an online survey hosted by Survey Sampling International (SSI) through their patient panels of self-reported diagnosis of AS or PsA. All panel members were recruited following a double opt-in process. Patients were fully profiled and pre-identified as having the disease of interest. They answered a series of questions to confirm that they met the inclusion criteria for the study using a screener module of the survey, which was completed prior to the full survey. For patients with AS, eligibility criteria included the ability to read and sign an informed consent form, age ≥ 18 years, self-reported diagnosis of active AS, treatment with secukinumab at the time of survey participation and continuous treatment since initiation, and willingness to complete the online survey. A separate survey for patients with PsA was administered to those meeting the eligibility criteria for PsA; results of the PsA analysis are reported elsewhere.

SSI uses a variety of contact methods to recruit online panels. Participants for this study were recruited through many channels, including partnerships with trusted loyalty programs, online banner advertisements, TV advertising, emails, apps, social media influencers, websites, and offline methods. SSI provided end-to-end operational services for the patient surveys, and was responsible for programming, hosting, and data collection for the web-based surveys. SSI was also responsible for questionnaire review, communication of online best practices, online survey testing and quality control, oversight of data collection and field update summaries, as well as review and quality control of data files and deliverables. RTI-HS managed the survey administration using the SSI data collection system. SSI developed and hosted the system on a secure server and RTI-HS performed user acceptance testing of the system. Patient data were entered directly into the SSI web-based survey platform. Contactable personal identifiers (including email address) were not stored with patient data, and study data were deidentified prior to exporting to RTI-HS.

Data management activities included the development and approval of the data management plan, all annotated data collection forms, data cleaning specifications document, and the testing of summary reports before the system was used live in the field. RTI-HS uses standard operating procedures to program, test, and manage hosting of the data system. User acceptance testing was conducted to ensure that the system met the requirements of the study. Data cleaning checks appeared in real time to alert the patients to missing and out-of-range data.

Each AS survey invitation included a unique survey link, embedded password for access to the survey, and a unique random-user identification number to ensure that each eligible participant completed the questionnaire only once. No personal identifiers were stored with the survey responses, and informed consent was obtained electronically from eligible patients interested in participating in the survey. No patient recruitment was conducted. Thus, approval from institutional review boards was not mandatory.

The survey questionnaire was developed under the guidance of practicing rheumatologist, Dr. Marina Magrey. The questionnaire was subsequently reviewed according to RTI-HS standard operating protocols. Data collected in the survey included demographics, clinical characteristics, co-morbidities, medication history (i.e., never taken, currently taking, taken over the past 12 months), AS symptoms (including pain disrupting sleep, fatigue, morning stiffness, pain and stiffness in the lower back and neck, soreness in areas other than joints, and ankle or heel pain \[indicating enthesitis\]), disease severity, and experience with secukinumab treatment. Disease activity and functional status at the time of survey participation were evaluated using the Bath Ankylosing Spondylitis Functional Index (BASFI) \[[@CR29]\] and BASDAI \[[@CR30]\] instruments. Each metric comprises a six- and eight-item questionnaire, respectively, with each question measured on a visual analog scale, resulting in a total score of 0--10, with higher scores indicating greater severity of disease or impairment of function.

Patients were asked to report their AS symptoms before and after initiating secukinumab treatment, time to symptom improvement, and satisfaction with secukinumab treatment in multiple domains, including symptom improvement, speed of symptom improvement, frequency of treatment, method of administration, ease of use, side effects (if any), and patient support services. With regard to satisfaction, patients were asked to denote whether they were "very satisfied," "mostly satisfied," "somewhat satisfied," or "not satisfied" with these domains; patients were considered satisfied if they denoted "very," "mostly," or "somewhat satisfied."

Data Analysis {#Sec4}
-------------

Descriptive analyses of patient demographics, self-reported disease severity, treatment history, AS symptoms, and treatment experience were conducted for all patients with AS who were included in the study. Mean, SD, median, interquartile range, and range were used to analyze continuous- or ordinal-type data. Frequencies and percentages were reported for categorical data. Each question was analyzed individually without any imputation of item-level missing data; no statistical hypothesis testing or sample weighting of questionnaire responses was performed in this study.

Results {#Sec5}
=======

Patient Demographics and Clinical Characteristics {#Sec6}
-------------------------------------------------

Of 2755 patients screened for participation in both the AS and PsA surveys, 200 eligible patients with AS, including 66 with both PsA and AS, completed the survey and were included in the analysis. Patient demographics and clinical characteristics are described in Table [1](#Tab1){ref-type="table"}. The mean (SD) age of included participants was 34.4 (10.6) years; 60.0% were male and 66.0% were White. The mean (SD) time since these patients first noticed symptoms of AS was 5.1 (5.7) years and the mean (SD) time since diagnosis was 3.9 (5.3) years; the mean (SD) age of these patients at the time of AS diagnosis was 30.3 (10.8) years. Patients were from all regions of the USA (East, 28.0%; South, 20.0%; Midwest, 21.5%; West, 17.0%; North, 11.0%; and a proportion of patients preferred not to answer, 2.5%); 62.5% were employed full time. All 200 patients reported one or more co-morbidity, the most common of which were anxiety (39.0%), PsA (33.0%), depression (31.5%), and chronic pain (28.5%); 81.5% of patients reported deformities due to AS. Patients had a mean (SD) BASDAI global score of 5.8 (2.25) and a mean (SD) BASFI global score of 5.5 (2.33).Table 1Patient demographics and disease characteristics among patients with ankylosing spondylitis (AS) who had been receiving secukinumab for ≥ 3 monthsCharacteristicPatients with AS (*N* = 200)Age, mean (SD), year34.4 (10.6)Male, *n* (%)120 (60.0)Race and/or ethnicity, *n* (%) White132 (66.0) Hispanic36 (18.0) Black/African American40 (20.0) Other/Prefer not to answer22 (11.0)Region, *n* (%) East56 (28.0) South40 (20.0) Midwest43 (21.5) West34 (17.0) North22 (11.0) Prefer not to answer5 (2.5)Employment status, *n* (%) Full time125 (62.5) Part time21 (10.5) Work at home9 (4.5) Student17 (8.5) Retired5 (2.5) Disabled/unable to work22 (11.0) Prefer not to answer1 (0.5)Time since symptom onset, mean (SD), years5.1 (5.7)Time since diagnosis, mean (SD), years3.9 (5.3)Current health conditions, *n* (%)^a^ Anxiety78 (39.0) Chronic pain57 (28.5) Depression63 (31.5) Fatigue64 (32.0) Psoriatic arthritis66 (33.0)BASDAI global score, mean (SD)5.8 (2.3)BASFI global score, mean (SD)5.5 (2.3)*BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BASFI* Bath Ankylosing Spondylitis Functional Index^a^Patient could select any comorbidities that apply

Treatment and Medication History {#Sec7}
--------------------------------

Of the 200 patients included, 33 (16.5%) had been receiving secukinumab for AS for 3--4 months, 39 (19.5%) for 5--6 months, 35 (17.5%) for 7--9 months, 36 (18.0%) for 10--12 months, and 57 (28.5%) for \> 12 months. Table [2](#Tab2){ref-type="table"} summarizes the current treatment and medication history of patients included in this study. Most patients (98.5%) had received prior treatment for AS, and of these, equal proportions (86.5%) were previously treated with nonbiologics (including NSAIDs, steroids, and physical therapy) and biologics; 27 patients (13.5%) were biologic naive. Among patients who had received prior treatment, 21 (10.9%) waited \< 1 week between stopping their previous treatment and initiating secukinumab, 45 (23.3%) waited 1 week to \< 1 month, 35 (18.1%) waited 1--2 months, 36 (18.7%) waited 2--3 months, 30 (15.5%) waited 3--4 months, and 26 (13.5%) waited ≥ 5 months. Among patients with prior treatment, 25.4% cited lack of efficacy as the main reason for stopping their last treatment; other reasons included side effects (22.8%), fear of injections/needles (14.5%), and high co-pay (10.9%) (Table [2](#Tab2){ref-type="table"}).Table 2Treatment history among patients with ankylosing spondylitis (AS) who had been receiving secukinumab for ≥ 3 monthsPatients with AS (*N* = 200)Duration of secukinumab treatment for AS, *n* (%) 3--4 months33 (16.5) 5--6 months39 (19.5) 7--9 months35 (17.5) 10--12 months36 (18.0) \> 12 months57 (28.5)Approximate time between stopping previous treatment and initiating secukinumab, *n* (%)^a^ \< 1 week21 (10.9) 1 week to \< 1 month45 (23.3) 1 to  \< 2 months35 (18.1) 2 to \< 3 months36 (18.7) 3--4 months30 (15.5) ≥ 5 months26 (13.5)Main reason for stopping previous treatment, *n* (%)^a^ Lack/loss of efficacy/effectiveness49 (25.4) Unwanted side effects44 (22.8) Anxiety/fear of injections/needles28 (14.5) Co-pay too high21 (10.9) Other reasons^b^51 (26.4)Past medication use, *n* (%) Over-the-counter NSAID174 (87.0) Prescription NSAID169 (84.5) Steroid106 (53.0) Physical therapy144 (72.0) Biologic173 (86.5) Never taken any nonbiologic treatment6 (3.0) Never taken any biologic treatment27 (13.5)*NSAID* nonsteroidal anti-inflammatory drug^a^Among patients who received a previous treatment for AS (*n* = 193)^b^Other reasons include "insurance would not pay," "treatment was not easy or convenient to take," "injection/infusion was painful," "frequency of dosing was too high," "number of required physician visits was too high," "number of required blood tests was too high," and "other"

Ankylosing Spondylitis Symptoms Before and After Secukinumab Initiation {#Sec8}
-----------------------------------------------------------------------

For all AS symptoms assessed in the online survey, including pain disrupting sleep, fatigue, morning stiffness, pain and stiffness in the lower back or neck, sore areas other than joints, and ankle or heel pain (suggesting enthesitis), the proportion of patients who reported experiencing the symptom after initiating secukinumab was lower than the proportion before secukinumab initiation (Fig. [1](#Fig1){ref-type="fig"}a). At the time of survey participation, 72 patients had been receiving secukinumab for 3--6 months, 71 for 7--12 months, and 57 for ≥ 12 months; the frequency of patient-reported symptoms with secukinumab treatment was lower in patients with longer duration of use (Fig. [1](#Fig1){ref-type="fig"}b--d). Patients who experienced a little better, moderately better, or much better improvement in AS symptoms since initiating secukinumab were further queried on when they started noticing symptom improvement (Fig. [2](#Fig2){ref-type="fig"}). Among patients who reported symptom improvement, 41.9% reported overall symptom improvement within 4 weeks after secukinumab initiation, 26.4% within 1--2 months, and 30.4% after 3 months; a similar trend was observed for each of the individual symptoms. Additionally, most (148 of 200 patients; 74.0%) reported overall improvement ("a little \[34.5%\]," "moderately \[21.0%\]," or "much better \[18.5%\]") in AS symptoms since secukinumab initiation compared with before secukinumab initiation; a similar trend was observed for all the individual symptoms analyzed (Fig. [2](#Fig2){ref-type="fig"}). Among 86 patients experiencing red and painful eyes, 53 (61.7%) reported improvement in this symptom since secukinumab initiation ("a little better," 16.3%; "moderately better," 22.1%; "much better," 23.3%); 42 of these 53 patients (79.2%) reported symptom improvement within 2 months of initiating secukinumab.Fig. 1Proportion of patients experiencing AS symptoms before and after initiating secukinumab in **a** the overall population (*N* = 200), **b** patients with 3--6 months of secukinumab use (*n* = 72), **c** patients with 7--12 months of secukinumab use (*n* = 71), and **d** patients with \> 12 months of secukinumab use (*n* = 57). *AS* ankylosing spondylitis Fig. 2Patient-reported time to first noticeable improvement in AS symptoms since secukinumab initiation. *AS* ankylosing spondylitis

Treatment Satisfaction with Secukinumab {#Sec9}
---------------------------------------

With regard to satisfaction with secukinumab treatment, most patients expressed overall satisfaction ("very," "mostly," or "somewhat satisfied") with secukinumab with regard to symptom improvement (99.0%), speed of symptom improvement (97.0%), frequency and method of administration (96.0% and 91.5%, respectively), ease of use (93.5%), patient support services (97.0%), and side effects, if any (93.0%) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Overall treatment satisfaction with secukinumab for AS (*n* = 193). *AS* ankylosing spondylitis

Discussion {#Sec10}
==========

We determined the feasibility of collecting measurable patient-reported experiences with regard to symptom improvement and treatment satisfaction by using a cross-sectional study to survey 200 patients with active AS in the USA. This was an exploratory endeavor to determine the practicality of capturing treatment-related experiences using simple questions that resonate with patients. The study design and interview questions will be applied to a large planned prospective study. Here, we evaluated patient experience with improvements in various AS symptoms and satisfaction with secukinumab treatment in a real-world setting. The majority of patients in our study reported overall symptom improvement since secukinumab initiation, and almost half of patients surveyed experienced overall improvement within 4 weeks of initiating secukinumab; \> 90% of patients expressed overall satisfaction with their treatment experience.

In AS clinical studies, emphasis is often placed on measuring treatment efficacy, disease activity, and limitations in physical function. Impairment in QOL, as associated with symptoms such as pain and fatigue \[[@CR31]\], and treatment satisfaction are not routinely measured during a clinic visit. A survey of 592 patients with rheumatic diseases, including AS and PsA, indicated that 30--50% of patients were seldom or never queried on the impact of their disease on QOL, and that normalization of QOL and symptom relief were the most important treatment attributes for these patients \[[@CR32]\]. In this study, we sought to understand treatment outcomes and satisfaction as verbalized by the patients. A large proportion of patients reported alleviation of AS symptoms with secukinumab with regard to pain, soreness, and stiffness, which was more pronounced with longer duration of secukinumab use, and overall satisfaction with the speed of symptom improvement, suggesting quicker resolution of these symptoms.

Improvement in pain and fatigue, in particular, is critical in mitigating the physical, social, and psychological aspects of AS \[[@CR33]\]. It is important to note that patients often endure other challenges stemming from their disease in addition to disease-specific symptoms. Data obtained from real-world studies can offer invaluable insight into the efficacy and safety of therapeutic agents among more diverse patient populations that are often unrepresented or under-represented in clinical trials with regard to factors such as age, ethnicity, differences in disease severity, and co-morbidities. Additionally, in our real-world study, approximately 87% of patients surveyed were biologic experienced compared with patients enrolled in clinical trials who are typically biologic naive \[[@CR34]--[@CR36]\]. Few studies have assessed the efficacy and safety of secukinumab in real-world settings \[[@CR37]--[@CR40]\]. Our study is the first to highlight patient-reported experiences with AS symptom improvement and treatment experience with secukinumab among patients with active AS in a US real-world setting, and may complement the efficacy data obtained from clinical trials.

As with all survey-based studies, patient perspectives may be subject to the patients' bias and experience. Physician-confirmed diagnosis and detailed treatment history were not available in this cross-sectional study; in addition, cross-sectional studies are not inherently representative of all patient populations. Furthermore, patient experiences before secukinumab initiation were based on patient recall. No inferences can be made on patient satisfaction and experience with secukinumab compared with specific previous treatments. Because our survey was offered online, only respondents with access to the Internet were able to participate. Our sample size of 200 patients may not be adequately powered for a complete analysis of patient satisfaction, and our patient recruitment method for this study did not allow for the selection of patients who have discontinued treatment with secukinumab. However, our objective was not to evaluate treatment experiences of patients who continued versus those who discontinued treatment; rather, the goal of this survey was to assess the feasibility of collecting patient perspectives on treatment experiences and satisfaction using a self-administered, online survey. A planned future study will examine patients' symptom improvement and experience with secukinumab compared with other biologic therapies as well as patient perspectives among secukinumab responders and nonresponders. Evaluating patient satisfaction is challenging, as "satisfaction" is a complex dynamic---while generic measures of treatment satisfaction exist \[[@CR41], [@CR42]\], no rheumatology-specific evaluations are currently available. We relied on perceived contribution of treatment to perceived health improvement, which may not be a correct inference. This study used patient-reported outcomes, such as symptom control and drug tolerability, as measures of satisfaction, and did not include clinical assessment. Additionally, no validated instrument was used to assess the magnitude of patient satisfaction; rather, satisfaction was measured on a 4-point gradient scale (e.g., very satisfied, mostly satisfied, somewhat satisfied, and not satisfied). The study also included some close-ended questions (i.e., questions with "yes" or "no" as answers), which may not adequately capture the nuances of patient experiences.

Conclusion {#Sec11}
==========

Using a web-based survey, the majority of patients with AS in our study who were treated with secukinumab reported improvement in AS symptoms since secukinumab initiation and expressed overall satisfaction with their treatment experience. Additionally, most reported experiencing improvements in their symptoms within a month of secukinumab initiation. Collection of real-world data and patient insights such as these provides perspectives that guide effective and comprehensive clinical decision making. This pilot endeavor indicates that assessment of symptom improvement and treatment satisfaction as conducted in our study is feasible and will be applicable in our future study for evaluation of these elements among responders and nonresponders of AS therapeutic agents.
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